Company Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
It has a collaboration with the University of Pennsylvania and the Children’s Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Steven Nichtberger |
Contact Details
Address: 2929 Arch Street, Suite 600 Philadelphia, Pennsylvania 19104 United States | |
| Phone | 267 759 3100 |
| Website | cabalettabio.com |
Stock Details
| Ticker Symbol | CABA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001759138 |
| CUSIP Number | 12674W109 |
| ISIN Number | US12674W1099 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science and Technology |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder and Co-Chair of Scientific Advisory Board |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder and Co-Chair of Scientific Advisory Board |
| Anup Marda M.B.A. | Chief Financial Officer |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer |
| Dr. Samik Basu M.D. | Chief Scientific Officer |
| Michael Gerard J.D. | General Counsel and Secretary |
| Heather Harte-Hall M.Sc. | Chief Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 5, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |